The first USC-licensed startup — a biotech company that has developed an intranasal drug delivery system for brain tumors — is now listed on Nasdaq. To celebrate the direct listing, the USC Stevens Center for Innovation and the startup, NeOnc Technologies Holdings Inc., rang the opening bell at 9:30 a.m. EDT/6:30 a.m. PDT on March 25.

NeOnc is based on intellectual property developed by neurosurgeon and NeOnc co-founder Thomas Chen, MD, PhD, of Keck Medicine of USC, who is also a tenured professor of neurological surgery and pathology with the Keck School of Medicine of USC. NeOnc is the first USC-licensed biotech company with agreements through USC Stevens to go public.

To continue reading, click here.